利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.027 秒)

    Tumor cells with increased immunogenicity and uses therfor
    1.
    发明申请
    Tumor cells with increased immunogenicity and uses therfor 有权
    肿瘤细胞具有增加的免疫原性，并使用其它药物

    公开(公告)号：US20060099195A1

    公开(公告)日：2006-05-11

    申请号：US11313556

    申请日：2005-12-20

    申请人： Suzanne Ostrand-Rosenberg ,  Sivasubramanian Baskar ,  Laurie Glimcher ,  Gordon Freeman ,  Lee Nadler

    发明人： Suzanne Ostrand-Rosenberg ,  Sivasubramanian Baskar ,  Laurie Glimcher ,  Gordon Freeman ,  Lee Nadler

    IPC分类号： A61K48/00

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70532 ,  C07K14/70539

    摘要： Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating-a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

    摘要翻译： 公开了修饰以表达T细胞共刺激分子的肿瘤细胞。 在一个实施方案中，共刺激分子是CD28 / CTLA4配体，优选B淋巴细胞抗原B7。 通过使用诱导或增加T细胞共刺激分子在肿瘤细胞表面上的表达或通过将T细胞共刺激分子与T细胞共刺激分子的偶联的试剂，可以通过用编码T细胞共刺激分子的核酸转染来修饰本发明的肿瘤细胞 肿瘤细胞表面。 还公开了进一步修饰以表达MHC I类和/或II类分子或其中抑制MHC相关蛋白（不变链）的表达的肿瘤细胞。 本发明的修饰的肿瘤细胞可用于治疗患有肿瘤的患者，预防或抑制肿瘤的转移性扩散或预防或抑制肿瘤复发的方法。 公开了特异性诱导针对肿瘤的CD4 + T细胞应答的方法和通过体内修饰肿瘤细胞治疗肿瘤的方法。

    Tumor cells with increased immunogenicity and uses therefor
    3.
    发明授权
    Tumor cells with increased immunogenicity and uses therefor 有权
    具有增加的免疫原性的肿瘤细胞及其用途

    公开(公告)号：US06319709B1

    公开(公告)日：2001-11-20

    申请号：US09450798

    申请日：1999-11-29

    申请人： Suzanne Ostrand-Rosenberg ,  Sivasubramanian Baskar ,  Laurie H. Glimcher ,  Gordon J. Freeman ,  Lee M. Nadler

    发明人： Suzanne Ostrand-Rosenberg ,  Sivasubramanian Baskar ,  Laurie H. Glimcher ,  Gordon J. Freeman ,  Lee M. Nadler

    IPC分类号： C12N1585

    CPC分类号： A61K39/0011 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/5152 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/70532 ,  C07K14/70539

    摘要： Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.

    摘要翻译： 公开了修饰以表达T细胞共刺激分子的肿瘤细胞。 在一个实施方案中，共刺激分子是CD28 / CTLA4配体，优选B淋巴细胞抗原B7。 通过使用诱导或增加T细胞共刺激分子在肿瘤细胞表面上的表达或通过将T细胞共刺激分子与T细胞共刺激分子的偶联的试剂，可以通过用编码T细胞共刺激分子的核酸转染来修饰本发明的肿瘤细胞 肿瘤细胞表面。 还公开了进一步修饰以表达MHC I类和/或II类分子或其中抑制MHC相关蛋白（不变链）的表达的肿瘤细胞。 本发明的修饰的肿瘤细胞可用于治疗患有肿瘤的患者，预防或抑制肿瘤的转移性扩散或预防或抑制肿瘤复发的方法。 公开了特异性诱导针对肿瘤的CD4 + T细胞应答的方法和通过体内修饰肿瘤细胞治疗肿瘤的方法。